FDA’s final guidance on prescription drug use-related software clarifies when companion app content is labeling, promotion or belongs in the PI.
On Oct. 20 the FDA finalized guidance setting out how drug sponsors should label, describe and submit content from software used alongside prescription medicines, from inhaler-connected apps to standalone dose reminders and symptom trackers. The agency said the framework resolves longstanding uncertainty over when app content is subject to FDA submission requirements.1
The guidance applies to software disseminated by or on behalf of a drug sponsor that produces an “end-user output” related to one or more of the sponsor’s drug products, whether or not the software is regulated as a device, according to the Federal Register notice.2 FDA defines that output as any content the software presents to the end user, such as a patient, caregiver or health care practitioner, and considers it a type of prescription drug labeling.
“Mobile apps are playing a growing role in how patients manage their medications and health conditions,” said Capt. Chris Wheeler, PharmD, director of the Division of Medical Policy Programs within CDER, in a press release. “This guidance helps ensure that the information these tools provide is accurate, evidence-based, and clearly communicated to both patients and their providers.”1
FDA said the guidance addresses three questions for industry: when app content is treated as FDA-required labeling versus promotional labeling, when an app should be referenced in a drug’s Prescribing Information (PI) and what companies should submit to FDA when they distribute app content to users.1 The notice describes the third area as when and how sponsors should submit end-user output to the agency for review.2
The guidance sorts companion software into two categories:1
“This guidance reflects FDA’s commitment to responsible, risk-proportionate oversight of digital health, an area that is a key priority for the agency and is evolving rapidly and holds significant promise for improving patient care,” said Michael Davis, MD, Ph.D., director of CDER.1 “By aligning our approach across drug and device centers, we are giving developers a clear and consistent pathway to bring safe, effective digital health technologies to patients.”1
According to the notice, the final version:2
The notice says the recommendations are intended to align with initiatives across FDA’s product centers, including digital health work at the Center for Devices and Radiological Health, to support coordinated review when the software is also reviewed as a device.2
The final guidance gives sponsors a defined test for companion app content. Content from most standalone apps will be treated as promotional material, consistent with
That matters because FDA treats an app’s end-user output as drug labeling, whether the sponsor or a technology partner built the app.2 That scope extends to adherence and coaching tools offered through
“Companion apps are quickly moving beyond simple dose reminders toward tools that adapt to each patient,” said Jared Seehafer, FDA deputy commissioner for technology and artificial intelligence.1 “Finalizing this guidance gives drug companies and their technology partners a stable foundation to build on as these technologies advance and helps ensure patients and providers can trust the information they receive.”
1. U.S. Food and Drug Administration. “FDA Issues Final Guidance on Prescription Drug Apps and Software.” Press release. October 20, 2026.
2. Food and Drug Administration, HHS. “Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability.” Federal Register public inspection document 2026-21516. Filed October 20, 2026; scheduled for publication October 21, 2026.
